The article “The Safety of MSC Therapy Over the Past 15 Years: A Meta-Analysis” evaluates the safety of mesenchymal stem cell (MSC) therapy across various populations and diseases. It includes 62 randomized clinical trials involving 3546 participants. The findings suggest that MSC therapy is generally safe, with common adverse events including transient fever, administration site issues, constipation, fatigue, and sleeplessness. The therapy also showed a trend toward reducing arrhythmia incidence. Overall, MSC therapy is considered safe compared to placebo treatments.